Clinical Genomics Expands Strategic Relationship with Quest Diagnostics and Further Increases Momentum for Innovative First-Line Colorectal Cancer Screening Blood Test
-- Advances key development milestones for the Trident Program --
-- Further strengthens strategic alliance with Quest Diagnostics focused on the Trident Program for CRC screening --
BRIDGEWATER, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of advanced cancer diagnostic solutions, including liquid biopsy tests, today announced key business updates related to Trident, the Company’s first-line Colorectal Cancer (“CRC”) screening blood test program, and its strategic alliance with Quest Diagnostics (NYSE: DGX) (“Quest”), the world's leading provider of diagnostic information services.
Trident Program for CRC Screening
Strategic Alliance with Quest Diagnostics
“These recent key advancements toward a pivotal study aimed at approval for commercialization will enable us to achieve our mission to save lives and reduce healthcare costs by providing easy-to-use and affordable tests for the detection and monitoring of colorectal cancer,” stated Betsy Hana, Chief Executive Officer of Clinical Genomics.
“Quest’s national network of laboratories, 2,250 patient service centers and employer population health solutions can provide broad access to any first-line blood test for CRC screening,” concluded Hanna.
“Quest is committed to ensuring that patients and providers in the U.S. have broad access to innovative colorectal cancer diagnostic services,” said Kristie Dolan, General Manager, Oncology, Quest Diagnostics. “Our continued collaboration with Clinical Genomics aligns with this commitment by advancing diagnostic innovations that aid in early diagnosis, which is shown to improve patient outcomes.”
About Clinical Genomics
About Quest Diagnostics
About Colorectal Cancer
Future Matters and Forward Looking Statements
Investor Relations for Clinical Genomics:
(1) United European Gastroenterology Week 2019, Poster presentation
COLVERA is a registered trademark of Clinical Genomics Pathology PTY Ltd.
Get Your Factories Connected -- Fast!
Keynote Roundtable Discussion